Key facts
- This page summarizes Sharon Shacham's Form 4 filing for Karyopharm Therapeutics Inc. (KPTI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Mar 2022, 16:17.
Sharon Shacham - 29 Mar 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- KPTI
- Reported as of
- 29 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Mar 2022, 16:17:01 UTC
- Prior SEC filing
- 02 Mar 2022
- Next SEC filing
- 09 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/Nancy Smith as Attorney-in-Fact for Sharon Shacham
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sharon Shacham filed Form 4 for Karyopharm Therapeutics Inc. (KPTI) on 31 Mar 2022.
Change
- Previous filing in this sequence was filed on 02 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KPTI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- +6.7%
- Price
- $0.000000
- Shares after
- 958,131
- Date
- 29 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
KPTI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 713,757
- Date
- 29 Mar 2022
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KPTI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +90,000
- Change %
- Price
- $0.000000
- Shares after
- 90,000
- Date
- 29 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $10.33
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
Footnote F2
This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.